[go: up one dir, main page]

AR057107A2 - Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos - Google Patents

Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos

Info

Publication number
AR057107A2
AR057107A2 ARP060103794A ARP060103794A AR057107A2 AR 057107 A2 AR057107 A2 AR 057107A2 AR P060103794 A ARP060103794 A AR P060103794A AR P060103794 A ARP060103794 A AR P060103794A AR 057107 A2 AR057107 A2 AR 057107A2
Authority
AR
Argentina
Prior art keywords
alkyl
group
hydrogen
phenyl
independently selected
Prior art date
Application number
ARP060103794A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23179892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057107(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR057107A2 publication Critical patent/AR057107A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de un antagonista CCR5 de la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la cual R es R8-fenilo, R8-piridilo, R8-tiofenilo o R8-naftilo; R1 es hidrogeno o alquilo C1-6; R2 es heteroarilo de 6 miembros substituido con R9, R10 y R11; N-oxido de heteroarilo de 6 miembros substituido con R9, R10 y R11; heteroarilo de 5 miembros substituido con R12 y R13; naftilo; fluorenilo; difenilmetilo, grupo de formulas (2) o formula (3); heteroarilo R3 es hidrogeno, alquilo C1-6; alcoxi C1-6-alquilo C1-6, cicloalquilo C3-10, cicloalquilo C3-10-alquilo C1-6, R8-fenilo, R8-fenilalquilo C1-6, R8-naftilo, R8-naftilalquilo C1-6, R8-heteroarilo o R8-heteroarilo o R8-heteroarilalquilo C1-6; R4, R5, R7 y R13 están independientemente seleccionados del grupo que consiste en hidrogeno y alquilo C1-6; R6 es hidrogeno, alquilo C1-6 o alquenilo C2-6; R8 representa de 1 a 3 subtituyentes independientemente seleccionados del grupo que consiste en hidrogeno, halogeno, alquilo C1-6, alcoxi C1-6, -CF3, CF3O-, CH3C(O)-, -CN, CH3SO2-, CF3SO2-, R14-fenilo, R14-bencilo, CH3C(=NOCH3), CH3C(=NOCH2CH3), formula (4); -NH2, -NHCOCF3, -NHCONH(alquilo C1-6), -NHCO(C1-6 alquilo), -NHSO2(alquilo C1-6), heteroarilo de 5 miembros y formula (5) donde X es -O-, -NH- o -N(CH3)-; R9 y R10 están independientemente seleccionados del grupo que consiste en alquilo C1-6, halogeno, -NR17R18, -OH, -CF3, -OCH3, -O-acilo, -PCF3 y -Si(CH3)3; R11 es R9, hidrogeno, fenilo, -NO2, -CN, -CH2F, -CHO, -CH=NOR17, piridilo, N,-oxido de piridilo, pirimidinilo, pirazinilo, -N(R17)CONR18R19, -NHCONH(cloro-alquilo C1-6), NHCONH(cicloalquilo C3-10-alquilo C1-6), NHCOalquilo C1-6, -NHCOCF3, -NHSO2N(alquilo C1-6)2, -NHSO2alquilo C1-6, -N(SO2CF3)2, - NHCO2alquilo C1-6, cicloalquilo C3-10, -SR20, -SOR20, -SO2R20, -SO2NH(alquilo C1-6), -OSO2alquilo C1-6, -OSO2CF3, hidroxialquilo C1-6, CONR17R18, -CON(CH2CH2-O-CH3)2, -OCONHalquilo C1-6, -C=2R17, -Si(CH3)3 o -B(OC(CH3)2)2; R12 es alquilo C1-6, -NH2 o R14-fenilo; R14 representa de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en hidrogeno, alquilo C1-C6, -CF3, -CO2R17, -CN, alcoxi C1-6 y halogeno; R15 y R16 están independientemente seleccionados del grupo que consiste en hidrogeno alquilo C1-C6 o R15 y R16 conjuntamente son un grupo alquileno C2-C5 y con el carbono al cual están unidos forman un anillo espiro de 3 a 6 átomos de carbono; R17, R18 y R19 están independientemente seleccionados del grupo que consiste en H y alquilo C1-6; y R20 es alquilo C1-C6 o fenilo; y uno o más agentes antivirales seleccionados del grupo que consiste en inhibidores de retrotranscriptasa nucleosídica, inhibidores de retrotranscriptasa no nucleosídica, inhibidores de proteasa, hidroxiurea, ribavirina, IL-2, IL-12, pentafusida y Yissum N° 11607 para la preparacion de un medicamento para tratar el virus de inmunodeficiencia humana a un humano que necesite dicho tratamiento.
ARP060103794A 1999-05-04 2006-08-30 Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos AR057107A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30522699A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
AR057107A2 true AR057107A2 (es) 2007-11-14

Family

ID=23179892

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP000102096A AR023823A1 (es) 1999-05-04 2000-05-02 Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos.
ARP060103792A AR057786A2 (es) 1999-05-04 2006-08-30 Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
ARP060103794A AR057107A2 (es) 1999-05-04 2006-08-30 Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
ARP060103793A AR057106A2 (es) 1999-05-04 2006-08-30 USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS
ARP060104839A AR057873A2 (es) 1999-05-04 2006-11-03 Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP000102096A AR023823A1 (es) 1999-05-04 2000-05-02 Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos.
ARP060103792A AR057786A2 (es) 1999-05-04 2006-08-30 Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP060103793A AR057106A2 (es) 1999-05-04 2006-08-30 USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS
ARP060104839A AR057873A2 (es) 1999-05-04 2006-11-03 Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos

Country Status (31)

Country Link
EP (2) EP1175401B1 (es)
JP (2) JP3722700B2 (es)
KR (1) KR100439358B1 (es)
AR (5) AR023823A1 (es)
AT (2) ATE299865T1 (es)
AU (2) AU780888B2 (es)
BR (1) BR0010304A (es)
CA (1) CA2371583C (es)
CH (1) CH1175401H9 (es)
CL (1) CL2008002737A1 (es)
CO (1) CO5170523A1 (es)
CZ (1) CZ20013940A3 (es)
DE (2) DE60045528D1 (es)
DK (1) DK1175401T3 (es)
EG (1) EG24136A (es)
ES (1) ES2244437T3 (es)
HK (1) HK1039930B (es)
HU (1) HUP0202867A3 (es)
IL (1) IL145741A0 (es)
MY (1) MY128367A (es)
NO (1) NO322045B1 (es)
PE (1) PE20010150A1 (es)
PL (1) PL203116B1 (es)
RU (1) RU2299206C9 (es)
SA (2) SA00210271B1 (es)
SI (1) SI1175401T1 (es)
SK (2) SK287418B6 (es)
TR (1) TR200103214T2 (es)
TW (1) TWI285200B (es)
WO (1) WO2000066558A1 (es)
ZA (1) ZA200108868B (es)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) * 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
EP1373206B1 (en) * 2001-03-29 2008-12-24 Schering Corporation Aryl oxime-piperazines useful as ccr5 antagonists
ES2342942T3 (es) 2001-03-29 2010-07-19 Schering Corporation Antagonistas de ccr5 utiles para el tratamiento del sida.
JP2005511693A (ja) * 2001-11-29 2005-04-28 シェーリング　コーポレイション 回転異性体の薬学的に活性な塩の量が増加した組成物の調製のためのプロセス
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
JP4671091B2 (ja) * 2002-03-18 2011-04-13 東レ・ファインケミカル株式会社 １−置換−２−メチルピペラジンの製造方法
CN100396676C (zh) * 2002-03-29 2008-06-25 先灵公司 作为ccr5拮抗药的哌啶和哌嗪化合物的合成
EP2141143A3 (en) * 2002-03-29 2010-05-05 Schering Corporation Stereoselective alkylation of chiral 2-methyl-4 protected piperazines
CA2483253A1 (en) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
JP2003335737A (ja) 2002-05-21 2003-11-28 Central Glass Co Ltd 光学活性（ｒ）−１−（４−トリフルオロメチルフェニル）エチルアミン
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
US20060251651A1 (en) * 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US20070043079A1 (en) * 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
MXPA05013474A (es) * 2003-06-13 2006-03-09 Schering Ag Derivados de quinolilamida como antagonistas de ccr-5.
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process
MXPA05013596A (es) 2003-06-30 2006-03-09 Schering Corp Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad.
JP4757802B2 (ja) 2003-11-03 2011-08-24 シェーリング コーポレイション ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2007520556A (ja) * 2004-02-05 2007-07-26 シェーリング　コーポレイション Ｃｃｒ３アンタゴニストとして有用なピペリジン誘導体
AU2005211499A1 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine CCR5 receptor modulators
CN1930136B (zh) 2004-03-05 2012-02-08 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物及有害生物防除剂
ES2431524T3 (es) * 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
ES2297727T3 (es) 2004-06-09 2008-05-01 F. Hoffmann-La Roche Ag Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
GB0417804D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
WO2006030925A1 (ja) 2004-09-13 2006-03-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
WO2006071958A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
MX2007008281A (es) 2005-01-06 2007-09-07 Schering Corp Preparacion de sales farmaceuticas de compuestos de piperazina.
MX2007010068A (es) * 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
WO2006088919A2 (en) * 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
BRPI0607946A2 (pt) * 2005-02-16 2009-10-20 Schering Corp piperazina-piperidinas substituìdas por pirazinila com atividade de antagonista cxcr3
CN101203509B (zh) * 2005-02-16 2013-05-08 默沙东公司 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶
EP1853587B1 (en) 2005-02-16 2011-08-03 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
EP1858887A1 (en) * 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
CN101189226A (zh) 2005-06-02 2008-05-28 霍夫曼-拉罗奇有限公司 哌啶-4-基-酰胺衍生物及它们作为sst受体亚型5拮抗剂的应用
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
JP2009517474A (ja) * 2005-11-30 2009-04-30 シェーリング コーポレイション Ｃｃｒ５拮抗剤およびｃｘｃｒ４拮抗剤の組み合わせを含む組成物
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AR059021A1 (es) 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8003642B2 (en) 2006-03-10 2011-08-23 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
PL2057125T3 (pl) 2006-08-16 2011-09-30 Hoffmann La Roche Nienukleozydowe inhibitory odwrotnej transkryptazy
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2671478C (en) 2006-12-13 2015-02-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
EP2142555A1 (en) 2007-03-29 2010-01-13 F. Hoffmann-Roche AG Heterocyclic antiviral compounds
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
CN101801952A (zh) * 2007-10-01 2010-08-11 弗·哈夫曼-拉罗切有限公司 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8367674B2 (en) 2008-04-17 2013-02-05 Concert Pharmaceuticals, Inc. Piperazine derivatives
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
KR101754698B1 (ko) 2008-12-19 2017-07-26 센트렉시온 테라퓨틱스 코포레이션 염증, 천식 및 ｃｏｐｄ 치료용 ｃｃｒ2 수용체 길항제로서의 사이클릭 피리미딘-4-카복스아미드
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
JP5658272B2 (ja) * 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
HRP20141143T1 (hr) 2009-12-17 2015-01-02 Boehringer Ingelheim International Gmbh Novi antagonisti receptora ccr2 i njihove uporabe
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802584B1 (en) 2012-01-13 2015-11-18 Novartis AG Salts of an ip receptor agonist
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
WO2016028971A1 (en) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
ATE272632T1 (de) * 1998-06-30 2004-08-15 Schering Corp Muskarin-rezeptor antagonisten

Also Published As

Publication number Publication date
EG24136A (en) 2008-08-06
DE60045528D1 (de) 2011-02-24
CA2371583C (en) 2005-09-13
PE20010150A1 (es) 2001-02-09
ES2244437T3 (es) 2005-12-16
NO20015366D0 (no) 2001-11-02
CA2371583A1 (en) 2000-11-09
CL2008002737A1 (es) 2009-01-16
EP1175401A1 (en) 2002-01-30
WO2000066558A1 (en) 2000-11-09
AU2005202357A1 (en) 2005-06-23
ATE299865T1 (de) 2005-08-15
DE60021370T2 (de) 2006-04-27
DE60021370D1 (de) 2005-08-25
TWI285200B (en) 2007-08-11
MY128367A (en) 2007-01-31
AU780888B2 (en) 2005-04-21
EP1632479B1 (en) 2011-01-12
RU2299206C2 (ru) 2007-05-20
AR057786A2 (es) 2007-12-19
EP1632479A2 (en) 2006-03-08
SA00210271B1 (ar) 2006-07-30
HUP0202867A2 (hu) 2003-01-28
PL203116B1 (pl) 2009-08-31
PL351388A1 (en) 2003-04-07
JP3722700B2 (ja) 2005-11-30
JP2002543185A (ja) 2002-12-17
ZA200108868B (en) 2003-01-27
KR100439358B1 (ko) 2004-07-07
SA06270096B1 (ar) 2009-02-25
JP2006052225A (ja) 2006-02-23
HK1039930B (en) 2005-12-09
SI1175401T1 (en) 2005-10-31
AU2005202357B2 (en) 2009-04-02
CZ20013940A3 (cs) 2002-04-17
CH1175401H9 (de) 2007-03-30
CH1175401H1 (de) 2007-02-15
CO5170523A1 (es) 2002-06-27
HK1039930A1 (en) 2002-05-17
IL145741A0 (en) 2002-07-25
EP1632479A3 (en) 2007-05-09
ATE495154T1 (de) 2011-01-15
BR0010304A (pt) 2002-02-13
DE60021370C5 (de) 2007-11-08
SK286641B6 (sk) 2009-03-05
RU2299206C9 (ru) 2007-11-20
KR20020019907A (ko) 2002-03-13
AU4500900A (en) 2000-11-17
AR023823A1 (es) 2002-09-04
SK15692001A3 (sk) 2002-07-02
NO20015366L (no) 2002-01-03
AR057106A2 (es) 2007-11-14
HUP0202867A3 (en) 2004-01-28
AR057873A2 (es) 2007-12-26
SK287418B6 (sk) 2010-09-07
NO322045B1 (no) 2006-08-07
EP1175401B1 (en) 2005-07-20
TR200103214T2 (tr) 2002-03-21
DK1175401T3 (da) 2005-11-14

Similar Documents

Publication Publication Date Title
AR057107A2 (es) Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20230238A1 (es) Inhibidores de kras g12c
AR005277A1 (es) Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
MX9803407A (es) Derivados de piperazina 1-(1,2-disustituido piperidinil)-4-sustituidos.
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
AR055878A1 (es) Derivados de ciclopropanocarboxamida
ATE212981T1 (de) 1-acyl-4-aliphatische aminopiperidin verbindungen
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
PE20020544A1 (es) Derivados de indolilmaleimida
AR049092A1 (es) Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina
NO910863L (no) N-(4-piperidinyl)(dihydrobenzofuran eller dihydro-2h-benzopyran)karboksamid-derivater og fremgangsmaate for deres fremstilling.
PE20030440A1 (es) Fenilsulfonamidas como antagonistas de ccr3
AR047008A1 (es) Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos.
TR199801210T2 (xx) 1-(1,2-�ift ikameli piperidinil)-4-(kayna�m�� imidazol)piperidin t�revleri.
AR063790A1 (es) Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismos
AR041246A1 (es) Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene
TR199801218T2 (xx) Takikinin antagonistleri olarak N-asil-2-ikameli-4-(Benzimidazolil-ya da imidazopiridinil-ikameli art�klar)-piperidinler.
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure